JP2022506781A5 - - Google Patents

Info

Publication number
JP2022506781A5
JP2022506781A5 JP2021524371A JP2021524371A JP2022506781A5 JP 2022506781 A5 JP2022506781 A5 JP 2022506781A5 JP 2021524371 A JP2021524371 A JP 2021524371A JP 2021524371 A JP2021524371 A JP 2021524371A JP 2022506781 A5 JP2022506781 A5 JP 2022506781A5
Authority
JP
Japan
Prior art keywords
amino acid
hla
acid sequence
seq
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021524371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506781A (ja
JP7558935B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060570 external-priority patent/WO2020097530A2/en
Publication of JP2022506781A publication Critical patent/JP2022506781A/ja
Publication of JP2022506781A5 publication Critical patent/JP2022506781A5/ja
Application granted granted Critical
Publication of JP7558935B2 publication Critical patent/JP7558935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524371A 2018-11-09 2019-11-08 メソテリンを標的とする免疫療法 Active JP7558935B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758397P 2018-11-09 2018-11-09
US62/758,397 2018-11-09
PCT/US2019/060570 WO2020097530A2 (en) 2018-11-09 2019-11-08 Immunotherapy targeting mesothelin

Publications (3)

Publication Number Publication Date
JP2022506781A JP2022506781A (ja) 2022-01-17
JP2022506781A5 true JP2022506781A5 (cg-RX-API-DMAC7.html) 2022-11-16
JP7558935B2 JP7558935B2 (ja) 2024-10-01

Family

ID=69160156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524371A Active JP7558935B2 (ja) 2018-11-09 2019-11-08 メソテリンを標的とする免疫療法

Country Status (13)

Country Link
US (1) US12595290B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877404A2 (cg-RX-API-DMAC7.html)
JP (1) JP7558935B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210102231A (cg-RX-API-DMAC7.html)
CN (1) CN113286815B (cg-RX-API-DMAC7.html)
AU (1) AU2019377553A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008973A8 (cg-RX-API-DMAC7.html)
CA (1) CA3119188A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191012A1 (cg-RX-API-DMAC7.html)
IL (1) IL282926A (cg-RX-API-DMAC7.html)
MX (1) MX2021005308A (cg-RX-API-DMAC7.html)
SG (1) SG11202104349QA (cg-RX-API-DMAC7.html)
WO (1) WO2020097530A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040454A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2022232599A1 (en) * 2021-04-30 2022-11-03 Regents Of The University Of Minnesota Mesothelin-specific t cell receptors and methods of using same
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
CN106459165B (zh) * 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
WO2017192924A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
KR102397771B1 (ko) 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
WO2018129270A1 (en) * 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy

Similar Documents

Publication Publication Date Title
Rosenberg Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
Criscitiello Tumor-associated antigens in breast cancer
Lee et al. DNA vaccines, electroporation and their applications in cancer treatment
Zhou et al. Breast cancer immunotherapy
Tsuboi et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A* 2402-binding residues
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
Baxevanis et al. Immunogenic HER-2/neu peptides as tumor vaccines
CN105622749B (zh) 癌抗原辅助肽
JP2022525099A5 (cg-RX-API-DMAC7.html)
Jäger et al. Vaccination for malignant melanoma: recent developments
ES2652017T3 (es) Métodos y composiciones farmacéuticas para el engaño inmunitario, particularmente útiles en el tratamiento de cáncer
AU2017275782A1 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
KR101454935B1 (ko) 면역치료용 크립틱 hla-b7 에피토프의 동정, 최적화 및 용도
Wang et al. Enhancing the immune response and tumor suppression effect of antitumor vaccines adjuvanted with non-nucleotide small molecule STING agonist
AR110857A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CN117187185A (zh) 一种工程化免疫细胞及其用途
Harada et al. Target molecules in specific immunotherapy against prostate cancer
JP2022547809A5 (cg-RX-API-DMAC7.html)
JP2025509573A (ja) 組換え融合タンパク質の組成物及びcar免疫細胞を作製するためのその使用方法
RU2022100330A (ru) Пептид, полученный из depdc1, и содержащая его вакцина
CA2634480C (en) Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
Velders et al. Identification of peptides for immunotherapy of cancer. It is still worth the effort
Smith et al. Immunotherapy of colorectal cancer
JP2020529847A5 (cg-RX-API-DMAC7.html)
McKee et al. T cell immunotherapy